Aurora Cannabis Inc. (ACB.TO)
CAD 6.11
(-4.83%)
CAD 6.11
(-4.83%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 236.8 Million CAD | -41.47% |
| 2022 | 404.61 Million CAD | -4.12% |
| 2021 | 422 Million CAD | -25.58% |
| 2020 | 567.03 Million CAD | -13.73% |
| 2019 | 657.24 Million CAD | -40.94% |
| 2018 | 1.11 Billion CAD | 220.15% |
| 2017 | 347.58 Million CAD | 235.03% |
| 2016 | 103.74 Million CAD | 734.35% |
| 2015 | 12.43 Million CAD | 28.27% |
| 2014 | 9.69 Million CAD | 1715.36% |
| 2013 | 533.98 Thousand CAD | 2093.42% |
| 2012 | 24.34 Thousand CAD | -47.83% |
| 2011 | 46.66 Thousand CAD | 202.2% |
| 2010 | 15.44 Thousand CAD | 0.79% |
| 2009 | 15.32 Thousand CAD | 83.94% |
| 2008 | 8330.00 CAD | 26.69% |
| 2007 | 6575.00 CAD | -55.69% |
| 2006 | 14.84 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | 269.32 Million CAD | -16.94% |
| 2023 Q2 | 258.97 Million CAD | -3.84% |
| 2023 Q3 | 236.8 Million CAD | -8.56% |
| 2023 FY | 236.8 Million CAD | -41.47% |
| 2022 Q4 | 324.25 Million CAD | -20.76% |
| 2022 Q2 | 428.85 Million CAD | -25.47% |
| 2022 FY | 404.61 Million CAD | -4.12% |
| 2022 Q3 | 409.18 Million CAD | -4.59% |
| 2022 Q1 | 575.43 Million CAD | 36.36% |
| 2021 Q2 | 530.72 Million CAD | -0.86% |
| 2021 Q1 | 535.34 Million CAD | -5.59% |
| 2021 FY | 422 Million CAD | -25.58% |
| 2021 Q4 | 422 Million CAD | -12.11% |
| 2021 Q3 | 480.16 Million CAD | -9.53% |
| 2020 Q2 | 633 Million CAD | 4.93% |
| 2020 FY | 567.03 Million CAD | -13.73% |
| 2020 Q4 | 567.03 Million CAD | -13.73% |
| 2020 Q3 | 657.26 Million CAD | 3.83% |
| 2020 Q1 | 603.29 Million CAD | -8.21% |
| 2019 FY | 657.24 Million CAD | -40.94% |
| 2019 Q2 | 848.11 Million CAD | -25.63% |
| 2019 Q1 | 1.14 Billion CAD | 2.48% |
| 2019 Q3 | 819.39 Million CAD | -3.39% |
| 2019 Q4 | 657.24 Million CAD | -19.79% |
| 2018 Q3 | 1.15 Billion CAD | 100.84% |
| 2018 Q1 | 552.44 Million CAD | 58.94% |
| 2018 FY | 1.11 Billion CAD | 220.15% |
| 2018 Q2 | 575.83 Million CAD | 4.23% |
| 2018 Q4 | 1.11 Billion CAD | -3.78% |
| 2017 Q4 | 347.58 Million CAD | 22.12% |
| 2017 FY | 347.58 Million CAD | 235.03% |
| 2017 Q3 | 284.62 Million CAD | 60.98% |
| 2017 Q2 | 176.8 Million CAD | 71.8% |
| 2017 Q1 | 102.91 Million CAD | -0.8% |
| 2016 Q4 | 103.74 Million CAD | 192.72% |
| 2016 Q1 | 15.67 Million CAD | 26.05% |
| 2016 Q2 | 23.39 Million CAD | 49.26% |
| 2016 Q3 | 35.44 Million CAD | 51.5% |
| 2016 FY | 103.74 Million CAD | 734.35% |
| 2015 Q2 | 10.98 Million CAD | 1.42% |
| 2015 Q1 | 10.82 Million CAD | 11.69% |
| 2015 FY | 12.43 Million CAD | 28.27% |
| 2015 Q4 | 12.43 Million CAD | 14.7% |
| 2015 Q3 | 10.84 Million CAD | -1.28% |
| 2014 Q2 | 4.76 Million CAD | 990.69% |
| 2014 FY | 9.69 Million CAD | 1715.36% |
| 2014 Q4 | 9.69 Million CAD | 73.14% |
| 2014 Q3 | 5.59 Million CAD | 17.47% |
| 2014 Q1 | 436.97 Thousand CAD | -18.17% |
| 2013 Q4 | 533.98 Thousand CAD | 7320.62% |
| 2013 FY | 533.98 Thousand CAD | 2093.42% |
| 2013 Q3 | 7196.00 CAD | 196.25% |
| 2013 Q2 | 2429.00 CAD | -81.11% |
| 2013 Q1 | 12.85 Thousand CAD | -47.19% |
| 2012 Q3 | 11.1 Thousand CAD | 38.57% |
| 2012 Q2 | 8015.00 CAD | -87.66% |
| 2012 Q1 | 64.94 Thousand CAD | 39.16% |
| 2012 FY | 24.34 Thousand CAD | -47.83% |
| 2012 Q4 | 24.34 Thousand CAD | 119.21% |
| 2011 Q4 | 46.66 Thousand CAD | 315.31% |
| 2011 Q3 | 11.23 Thousand CAD | 1277.08% |
| 2011 Q2 | 816.00 CAD | -92.17% |
| 2011 Q1 | 10.42 Thousand CAD | -32.49% |
| 2011 FY | 46.66 Thousand CAD | 202.2% |
| 2010 Q1 | 12.08 Thousand CAD | -21.13% |
| 2010 Q3 | 169.00 CAD | -95.2% |
| 2010 Q4 | 15.44 Thousand CAD | 9037.87% |
| 2010 FY | 15.44 Thousand CAD | 0.79% |
| 2010 Q2 | 3524.00 CAD | -70.84% |
| 2009 FY | 15.32 Thousand CAD | 83.94% |
| 2009 Q3 | 1957.00 CAD | 153.17% |
| 2009 Q1 | 11.49 Thousand CAD | 38.04% |
| 2009 Q2 | 773.00 CAD | -93.28% |
| 2009 Q4 | 15.32 Thousand CAD | 682.93% |
| 2008 Q2 | - CAD | -100.0% |
| 2008 Q4 | 8330.00 CAD | 2447.4% |
| 2008 FY | 8330.00 CAD | 26.69% |
| 2008 Q1 | 6277.00 CAD | -4.53% |
| 2008 Q3 | 327.00 CAD | 0.0% |
| 2007 Q2 | 5169.00 CAD | -58.91% |
| 2007 Q1 | 12.58 Thousand CAD | 0.0% |
| 2007 FY | 6575.00 CAD | -55.69% |
| 2007 Q4 | 6575.00 CAD | 16.21% |
| 2007 Q3 | 5658.00 CAD | 9.46% |
| 2006 FY | 14.84 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Avicanna Inc. | 13.99 Million CAD | -1591.571% |
| Avant Brands Inc. | 33.22 Million CAD | -612.747% |
| Cardiol Therapeutics Inc. | 8.45 Million CAD | -2701.076% |
| Crescita Therapeutics Inc. | 5.77 Million CAD | -3999.775% |
| Knight Therapeutics Inc. | 198.62 Million CAD | -19.223% |
| MediPharm Labs Corp. | 10.93 Million CAD | -2066.145% |
| OrganiGram Holdings Inc. | 26.83 Million CAD | -782.54% |
| Canopy Growth Corporation | 799.82 Million CAD | 70.393% |
| Willow Biosciences Inc. | 3.23 Million CAD | -7215.508% |
| Auxly Cannabis Group Inc. | 210.85 Million CAD | -12.305% |